BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.17.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261103
DTEND;VALUE=DATE:20261124
DTSTAMP:20260709T125124Z
CREATED:20260709T125124Z
LAST-MODIFIED:20260709T125124Z
UID:43917-1793664000-1795478399@www.pharmajournalist.com
SUMMARY:10th Dermatology Drug Development Summit
DESCRIPTION:10th Dermatology Drug Development Summit – Discovering\, Developing & Commercializing Next-Generation Inflammatory Skin Disease Therapeutics – November 3-5\, 2026 | Boston\, MA \nThe 10th Dermatology Drug Development Summit returns in 2026 as the leading premier forum dedicated to advancing the discovery\, development\, and commercialization of innovative therapies for inflammatory skin disease. \nMarking a decade of convening the field’s most influential voices\, this year’s summit arrives at a pivotal moment: As competition intensifies across atopic dermatitis and psoriasis\, developers are under growing pressure to demonstrate meaningful differentiation\, accelerate development timelines and identify the next generation of high-value opportunities beyond today’s established targets and therapies. \nDesigned as an intimate\, discussion-led forum\, the summit brings together more than 90 experts spanning discovery\, translational medicine\, preclinical development\, clinical strategy\, medical affairs\, and commercial functions. \nThe meeting provides a unique opportunity to benchmark emerging science\, evaluate novel targets\, and share practical lessons from across the dermatology pipeline. \nAttendees will hear from 40+ senior leaders representing major pharmaceutical companies\, innovative biotechs\, academic research centers\, and patient advocacy organizations\, with representation from AbbVie\, Galderma\, Merck\, SUN Pharma\, Eli Lilly\, UNION Therapeutics and others. \nThis year’s agenda features dual content tracks including Discovery & Preclinical and Clinical & Commercial. \nNew additions include a Pre-Conference Workshop Day\,  offering interactive deep dives into two of dermatology’s fastest-growing areas of innovation: hidradenitis suppurativa\, exploring strategies to drive earlier intervention and disease modification\, and rare & ultra-rare inflammatory skin diseases\, examining how developers can generate meaningful evidence\, overcome translational challenges and unlock scalable opportunities across underserved patient populations. \nWith 10+ hours of in-person networking\, the summit fosters meaningful collaboration among scientists\, clinicians\, executives\, and decisionmakers working to discover\, develop and commercialize the next wave of precision therapeutics. \nFor organizations committed to shaping the future of inflammatory skin disease drug development\, the Dermatology Drug Development Summit remains the essential annual meeting to align on emerging science\, evolving standards of care\, and the path to impactful patient outcomes. \nFind out more about the 10th Anniversary Edition of the Dermatology Drug Development Summit: https://ter.li/rcr0mcj
URL:http://www.pharmajournalist.com/event/10th-dermatology-drug-development-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261117
DTEND;VALUE=DATE:20261120
DTSTAMP:20260813T160131Z
CREATED:20260813T160131Z
LAST-MODIFIED:20260813T160131Z
UID:44184-1794873600-1795132799@www.pharmajournalist.com
SUMMARY:2nd Model-Informed Drug Development Summit 2026
DESCRIPTION:As model-informed drug development (MIDD) becomes increasingly central to modern drug development strategy\, organizations are under growing pressure to leverage quantitative approaches that accelerate timelines\, reduce risk\, and improve regulatory and clinical success. The 2nd Model-Informed Drug Development Summit\, taking place November 17-19\, 2026\, in Boston\, MA\, brings together senior leaders in pharmacometrics\, clinical pharmacology\, quantitative sciences\, translational medicine\, and regulatory science to explore how modelling is transforming decision-making across the entire development lifecycle. \nDesigned as an intimate and highly interactive forum\, this summit moves beyond traditional large-scale industry meetings to provide meaningful peer-to-peer networking\, practical case studies\, and candid discussions on the real-world challenges of implementing MIDD strategies. Attendees will gain insights from leading organizations including FDA\, Health Canada\, Sanofi\, Eli Lilly\, GSK\, AbbVie\, Novartis\, Amgen\, Genentech\, Gilead Sciences\, BMS\, Astellas Pharma\, Vertex Pharmaceuticals\, Johnson & Johnson\, and Genmab. \nThe agenda explores the latest industry developments\, including implementation of the finalized ICH M15 guideline\, the growing role of quantitative systems pharmacology (QSP)\, advances in AI-enabled modelling\, and the use of real-world evidence to strengthen development decisions. Through case studies\, panel discussions\, workshops\, and roundtable sessions\, attendees will learn how to optimize dose selection\, improve trial design\, accelerate rare disease programs\, validate model outputs\, demonstrate return on investment from MIDD initiatives\, and strengthen regulatory submissions. \nIn addition to the main conference\, dedicated workshops will examine how to integrate pharmacometrics\, QSP\, machine learning\, and AI into connected modelling ecosystems\, while also addressing the challenge of building internal and external stakeholder confidence in modelling approaches. \nWith more than 60 senior industry leaders expected to attend\, the summit offers a unique opportunity to benchmark strategies\, share best practices\, build valuable partnerships\, and stay ahead of evolving regulatory and scientific expectations. Whether you are advancing innovative therapies\, refining quantitative development strategies\, or exploring the future role of AI in drug development\, this event provides the practical insights and connections needed to maximize the impact of model-informed approaches across your organization. \nTo learn more about the event and register online click here.
URL:http://www.pharmajournalist.com/event/2nd-model-informed-drug-development-summit-2026/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261203
DTSTAMP:20260811T120601Z
CREATED:20260811T103702Z
LAST-MODIFIED:20260811T120601Z
UID:44144-1795996800-1796255999@www.pharmajournalist.com
SUMMARY:Novel CNS Biomarkers Summit Europe
DESCRIPTION:Introducing Europe’s first CNS Biomarker Forum. The Novel CNS Biomarkers Summit Europe is the only European meeting dedicated exclusively to advancing fluid\, imaging\, and digital biomarkers for CNS drug development. Bringing together biomarker\, translational medicine\, neuroscience\, and clinical development leaders\, the summit focuses on accelerating the discovery\, validation\, and implementation of next-generation biomarkers across neurodegenerative and neurological diseases. \nAs landmark advances in blood-based Alzheimer’s diagnostics\, digital biomarkers\, multimodal approaches\, and precision medicine continue to reshape the field\, attendees at the Novel CNS Biomarkers Summit Europe will explore strategies to improve patient stratification\, demonstrate target engagement\, generate earlier efficacy signals\, and de-risk CNS drug development programmes. \nCompanies attending the Novel CNS Biomarkers Summit Europe: \n\nRoche\n\n\nUCB\n\n\nLundbeck\n\n\nServier\n\n\nNRG Therapeutics\n\n\nImmunic Therapeutics\n\n\nProgenra\n\n\nSaniona\n\n\nBial\n\n…and more! \nWhy attend the Novel CNS Biomarkers Summit Europe? \n\nJoin 60+ biomarker and translational medicine leaders\n\n\nGain insights from 17+ expert speakers\n\n\nExplore biomarker strategies across 6+ CNS indications\n\n\nParticipate in interactive workshops and networking opportunities\n\nDiscover the brand-new event programme now for more information on sessions and how to register your place.
URL:http://www.pharmajournalist.com/event/novel-cns-biomarkers-summit-europe/
LOCATION:The Hilton London Olympia\, 380 Kensington High St\, Kensington\, London\, W14 8N\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261204
DTSTAMP:20260805T090545Z
CREATED:20260805T090501Z
LAST-MODIFIED:20260805T090545Z
UID:44111-1796083200-1796342399@www.pharmajournalist.com
SUMMARY:8th CNS Drug Delivery Summit
DESCRIPTION:The 8th CNS Drug Delivery Summit is the leading industry forum dedicated to overcoming the challenges of delivering therapeutics across the blood-brain barrier and into the central nervous system. \nBringing together experts from biopharma\, biotech\, and academia\, the summit will explore the latest advances in drug delivery technologies\, including nanoparticles\, antibody shuttles\, gene therapy vectors\, focused ultrasound\, and intranasal delivery. Attendees will gain practical insights into improving drug penetration\, optimising biodistribution\, and advancing therapies for neurological and neurodegenerative diseases. \nThrough scientific presentations\, case studies\, and interactive discussions\, the event will address key translational\, clinical\, manufacturing\, and regulatory challenges while showcasing innovative approaches that can accelerate CNS drug development. \nJoin a collaborative community of drug developers\, technology innovators\, and scientific leaders committed to unlocking the next generation of CNS therapies and improving outcomes for patients worldwide. \nFind out more today: https://ter.li/08gi5jio
URL:http://www.pharmajournalist.com/event/8th-cns-drug-delivery-summit/
LOCATION:Hyatt Regency Boston Harbor\, 101 Harborside Drive\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261208
DTEND;VALUE=DATE:20261211
DTSTAMP:20260813T155514Z
CREATED:20260813T155514Z
LAST-MODIFIED:20260813T155514Z
UID:44179-1796688000-1796947199@www.pharmajournalist.com
SUMMARY:World CNS Summit South Korea
DESCRIPTION:The World CNS Summit South Korea is the premier industry-focused forum dedicated to advancing targeted\, mechanism-differentiated therapies for neurodegenerative\, rare neurodevelopmental\, and neuropsychiatric disorders. As South Korea emerges as a major center for neuroscience innovation\, the summit convenes biopharma leaders\, translational scientists\, and drug developers to explore the next generation of CNS therapeutics and accelerate progress from discovery through early clinical development. \nThe agenda highlights advances in disease-modifying approaches\, blood-brain barrier delivery technologies\, RNA-based therapeutics\, gene therapies\, neuroinflammation\, biomarkers\, and novel targets beyond traditional amyloid and tau pathways. Attendees will gain insights from leading organizations including ABL Bio\, AriBio\, Johnson & Johnson\, Eli Lilly\, Novartis\, Takeda\, AbbVie\, Lundbeck\, Angelini Pharma and many more. \nDesigned to foster meaningful scientific exchange and strategic collaboration\, the summit provides a valuable platform to connect with Korean biotech innovators\, global pharmaceutical companies\, and external innovation leaders evaluating the next wave of CNS opportunities. For decision-makers shaping neuroscience pipelines\, partnerships\, and licensing strategies\, it offers a focused view of the technologies\, modalities\, and therapeutic approaches driving the future of CNS drug development. \nFind out more today: https://ter.li/jrf94t4n
URL:http://www.pharmajournalist.com/event/world-cns-summit-south-korea/
LOCATION:Grand Hyatt Incheon 208 Yeongjonghaeannam-ro\, 321 Beon-gil\, Yeongjong-gu\, 23358\,  Incheon South Korea
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261208
DTEND;VALUE=DATE:20261211
DTSTAMP:20260813T160546Z
CREATED:20260813T160546Z
LAST-MODIFIED:20260813T160546Z
UID:44189-1796688000-1796947199@www.pharmajournalist.com
SUMMARY:10th Complement-Based Drug Development Summit
DESCRIPTION:The 10th Complement-Based Drug Development Summit returns at a pivotal moment as the field shifts from validating complement biology to maximizing its clinical and commercial potential. As pipelines expand beyond C3 and C5 and competition intensifies\, developers are focused on identifying the right targets\, modalities\, and indications to drive differentiation and patient impact. Recent milestones\, including Regeneron’s cemdisiran advancing through FDA and EMA review and Biogen’s acquisition of Apellis\, highlight the growing momentum and investment shaping the next era of complement therapeutics. \nAs the industry’s only dedicated forum uniting complement leaders\, this meeting will address the strategic and scientific priorities shaping the next generation of complement therapeutics\, including: \n\nAdvancing clinical success through biomarker innovation\, improved target engagement strategies\, robust trial design\, and smarter indication selection to de-risk development\n\n\nBenchmarking next-generation modalities across siRNA\, gene therapy\, biologics\, and novel delivery technologies to improve durability\, efficacy\, safety\, and patient outcomes\n\n\nExpanding beyond C3 and C5 to evaluate intracellular complement biology\, emerging targets\, novel mechanisms\, and combination approaches shaping the next generation of complement therapeutics\n\n\nUnlocking growth beyond renal disease by assessing the translational and clinical opportunity across neurodegenerative\, ocular\, autoimmune\, haematological\, oncology\, and acute indications\n\nWhat to Expect: \n\n80+ Experts Dedicated to Complement\n\n\n18+ Data-Driven Presentations\n\n\n7+ Hours of Meaningful Networking\n\n\n2 Discussion-Led Workshops\n\n\n1 Scientific Poster Session\n\nBringing together biotech innovators\, pharma leaders\, and academic KOLs\, this industry-led anniversary meeting provides a focused opportunity to advance novel targets\, refine modality strategy\, navigate clinical development\, and expand into new indications. \nBy attending\, you’ll be in the room with: Annexon Biosciences\, Apellis Pharmaceuticals\, Cascade Biotechnology\, Complement Therapeutics\, Graviton Biosciences\, Genentech\, Grid Therapeutics\, Ikarovec\, Inflarx\, Regeneron\, Ripple Therapeutics\, Sanofi and more! \nAcross 3 days of discussion-led workshops\, data-driven presentations\, clinical insights\, and expert panels\, engage with the leaders behind renal readouts\, next-generation targets\, and emerging CNS and ophthalmology programs to benchmark your approach\, strengthen differentiation\, and build partnerships that de-risk complement drug development. \nDiscover the 10th Anniversary Meeting program here: https://ter.li/2yscb7oh
URL:http://www.pharmajournalist.com/event/10th-complement-based-drug-development-summit/
LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR